(BJU Int[TA])
13,436 results
  • Response evaluation of neoadjuvant therapy in MIBC: clinical trial-derived evidence to guide practice. [Review]
    BJU Int. 2026 Aug 05. [Online ahead of print]Contieri R, van Rhijn BWG, … EAU Imaging SectionBI
  • CONCLUSIONS: Response assessment after NAT in MIBC remains insufficiently standardised. Trial-derived evidence supports cross-sectional imaging before radical local treatment, with CT the most established modality, largely reflecting trial-design conventions and availability rather than demonstrated diagnostic superiority; bladder MRI is more accurate for local restaging. Emerging biomarkers such as ctDNA require validation. Harmonising timing, modalities and response definitions is needed to enable evidence-based treatment adaptation.
  • Symptom-guided reduction of BCG dwell time: findings from the north-REG randomized trial. [Journal Article]
    BJU Int. 2026 Jul 31. [Online ahead of print]Munk L, Hyldgaard JM, … Graugaard-Jensen CBI
  • CONCLUSIONS: Daily electronic patient-reported outcomes monitoring revealed that patients with NMIBC have a high baseline symptom burden prior to BCG therapy. Symptom-guided DT reductions may reduce local urgency and systemic toxicity and improve treatment tolerability. However, treatment completion does not seem to be affected.
  • Small- and large-calibre ureteroscopes: an updated systematic review and meta-analysis. [Review]
    BJU Int. 2026 Jul 28. [Online ahead of print]Di Bello F, Verri P, … Emiliani EBI
  • CONCLUSIONS: Within the present meta-analysis, the small-calibre ureteroscopes achieved comparable outcomes to large-calibre ureteroscopes. To overcome the substantial heterogeneity and residual confounding across studies, well-designed and adequately powered RCTs are required.
  • INtraVESical immunoTherapy (INVEST) prior to radical cystectomy for bladder cancer: trial protocol. [Journal Article]
    BJU Int. 2026 Jul 27. [Online ahead of print]Lister-Whelan R, Senior E, … Hussain SABI
  • High-risk non-muscle-invasive bladder cancer (HRNMIBC) has a variable prognosis, managed predominantly by local surgical resection and intravesical Bacillus Calmette-Guérin (BCG), or radical cystectomy (RC). Current treatments are poorly tolerated, have supply limitations and often fail to control the disease. Treatments overcoming these limitations are needed to improve HRNMIBC outcomes. Many no…